1. Scrip
  2. >>Business

Novo Nordisk To Target 'New GLP-1 Patients Only' With Weekly Ozempic

 
• By Sten Stovall

Novo Nordisk's head of international operations says trying to switch diabetes patients over to newly approved Ozempic from other GLP-1 medicines is not part of its commercial strategy.

Diabetes
Ozempic Is Newest Once-Weekly GLP-1 Agonist To Reach Market For Type 2 Diabetes • Source: Shutterstock

Novo Nordisk AS will not actively try to get existing diabetes patients who currently use human glucagon-like peptide-1 agonists to swap over to its newly approved once-weekly injectable Ozempic (semaglutide), "because the GLP-1 market is growing, and it's good to have more options, so the main focus will be on capturing new starts," according to the group's international operations chief Maziar Mike Doustdar.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.